Post-licensure Safety Study of IMOJEV® in Thailand

Status Active, not recruiting

Clinical Trial Summary

The aim of this study is to further characterize the safety profile of IMOJEV®.

Primary Objective:

- To describe serious adverse events (SAEs, including adverse events of special interest [AESIs]) up to 60 days after administration of one dose of IMOJEV®.

Secondary Objective:

- To describe Grade 3 (severe) systemic Adverse Events (AEs) up to 30 minutes after administration of one dose of IMOJEV®.

Clinical Trial Description

Participants aged 1 year to less than 5 years will be randomized to receive one injection of IMOJEV® either as a primary vaccination or as a booster. Safety data will be collected for 60 days after IMOJEV® vaccination. The duration of each subject's participation in the trial will be 60 days. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01981967
Study type	Interventional
Source	Sanofi
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	November 2013
Completion date	June 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03282370` - Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam	Phase 3
Recruiting	`NCT05568953` - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity	Phase 2
Completed	`NCT00776230` - Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling	Phase 3
Completed	`NCT00594958` - Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51	Phase 3
Completed	`NCT00595790` - Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51	Phase 3
Completed	`NCT00604708` - Immunogenicity Study of the Japanese Encephalitis Vaccine IC51	Phase 3
Completed	`NCT00596271` - Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440	Phase 3
Not yet recruiting	`NCT01954810` - Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children	Phase 4
Completed	`NCT01246479` - Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study	Phase 3
Completed	`NCT00605085` - Safety and Tolerability of the Japanese Encephalitis Vaccine IC51	Phase 3
Completed	`NCT00595270` - Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51	Phase 3
Completed	`NCT00596102` - Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51	Phase 3
Completed	`NCT00314132` - Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.	Phase 3
Completed	`NCT01466387` - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Phase 3
Completed	`NCT00314145` - A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX	Phase 3
Completed	`NCT00981630` - Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine	Phase 2
Completed	`NCT01567865` - Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine	Phase 4
Completed	`NCT01656200` - A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2	Phase 4
Unknown status	`NCT01163123` - Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan	N/A
Completed	`NCT01856205` - Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis	Phase 2